Loading...
•
Sep 30, 2023
Ionis Q3 2023 Earnings Report
Ionis reported financial results for Q3 2023, highlighting progress in regulatory approvals and pipeline development.
Key Takeaways
Ionis Pharmaceuticals reported Q3 2023 financial results, with total revenue of $144 million. The company is on track for potential U.S. approval of eplontersen and reported positive data from the olezarsen Phase 3 Balance study. Strategic investments in eplontersen, olezarsen, and donidalorsen contributed to increased operating expenses.
Total revenue reached $144 million, driven by commercial and R&D revenues.
Eplontersen is under regulatory review in the EU and Canada, with potential U.S. approval in December 2023.
Positive data was reported from the olezarsen Phase 3 Balance study, positioning it for potential commercial launch.
Advanced zilganersen into Phase 3 development for Alexander disease.
Ionis
Ionis
Ionis Revenue by Segment
Revenue by Segment
SPINRAZA royalties Revenue
CapyFin.comTEGSEDI and WAYLIVRA Revenue
CapyFin.com Forward Guidance
Ionis is on track to achieve its 2023 financial guidance, supported by a strong financial foundation, significant royalty revenue from SPINRAZA, and substantial R&D revenue from multiple partners. The company is well-positioned to invest in key priorities to drive future positive cash flow.
Positive Outlook
- Potential U.S. eplontersen ATTRv-PN approval next month followed closely by launch
- Strong financial foundation with more than $2B in cash
- Significant royalty revenue with SPINRAZA
- Substantial and sustained R&D revenue from multiple partners
- Advancing go-to-market activities
Revenue & Expenses
Visualization of income flow from segment revenue to net income